RKVTF (Rakovina Therapeutics) Research & Development: $3.33 Mil (TTM As of Mar. 2026)


RKVTF Rakovina Therapeutics Inc RKVTF
34 GF Score
Price $0.09
! 1 Warning Sign
View Full Analysis

What is Rakovina Therapeutics Research & Development?

Rakovina Therapeutics RKVTF +0.11% 34 Research & Development is $3.33 Mil as of Mar. 2026. GuruFocus rates RKVTF with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Rakovina Therapeutics's Research & Development for the three months ended in Mar. 2026 was $0.75 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $3.33 Mil.

Rakovina Therapeutics  (OTCPK:RKVTF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Rakovina Therapeutics Research & Development Related Terms

Rakovina Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Rakovina Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rakovina Therapeutics Research & Development Chart

Rakovina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
1.17 1.44 1.25 1.64 3.34

Rakovina Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 1.18 0.80 0.60 0.75
RKVTF
34GF Score
Rakovina Therapeutics Inc RKVTF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rakovina Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $3.33 Mil mean?
Rakovina Therapeutics (RKVTF) has a Research & Development of $3.33 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Rakovina Therapeutics and its competitors.
Is Rakovina Therapeutics' Research & Development too high?
Rakovina Therapeutics' current Research & Development is $3.33 Mil. Overall, Rakovina Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Rakovina Therapeutics' Research & Development compare to VRTX and REGN?
Rakovina Therapeutics' Research & Development of $3.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Rakovina Therapeutics and its competitors. Rakovina Therapeutics's current Research & Development is $3.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rakovina Therapeutics stock overvalued right now?
Rakovina Therapeutics (RKVTF) has a current Research & Development of $3.33 Mil. The current Research & Development is $3.33 Mil. Rakovina Therapeutics' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Rakovina Therapeutics (RKVTF), the current Research & Development is $3.33 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rakovina Therapeutics Business Description

Other Exchanges 7JO0:GermanyRKV:Canada
Address 999 West Broadway, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Rakovina Therapeutics Inc is a biopharmaceutical research company focused on the development of cancer treatments. Its work is based on technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using proprietary, generative AI platforms. By using AI, it can review and optimize drug candidates at a greater pace. The company has established a pipeline of distinctive DNA-damage response inhibitors to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Its drug development pipeline consists of candidates like kt-5000AI, kt-2000AI, and kt-3283, targeting solid tumours and PARP-resistant adult and childhood cancers.
34GF Score

Get the complete analysis for RKVTF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.09
Price